Collegium Pharmaceutical (COLL) stock
COLL's Quality Score was unchanged on Mon, Oct 5, at 2.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Why it's down
Down 41% in 3 months, 18% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−3Long-term trend below a falling 200-day average, down over one year, down over two years
Why COLL lags the market
Collegium Pharmaceutical returned -5% over three years to the S&P 500's +89%; revenue grew 18.9% a year against its 3 peers' median of 28.3%.
2 drivers, the timeline, and the peer table, for Pro members
What's next
Expected to report Thu Nov 5, before the open
After its last 4 reports it closed -0.2% on average, higher 2 of 4 times.
What would turn COLL's score around: 5 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
COLL has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1429.9
- MACD (12, 26, 9)Above signal
- 50-day average$26.49
- 200-day average$35.61
- ADX 1438.5
- Support$21.65
- Resistance$23.69
- Bollinger Bands (20, 2)Inside
- Volume1.1x
How COLL ranks in Biotech
COLL is #125 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
CMPXOpen for its score
COGTOpen for its score
CRBPOpen for its score
COLL1/142
When does COLL report earnings, and what happens after?
Expected to report Thu Nov 5, before the open (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026Before open | Before open | -11.4% | -18.6% | -28.1% |
| May 7, 2026Before open | Before open | +2.7% | +7.7% | -4.5% |
| Feb 26, 2026Before open | Before open | -8.7% | -3.3% | -13.4% |
| Nov 6, 2025Before open | Before open | +11.7% | +13.4% | +32.1% |
Who is trading COLL
COLL trades by Congress and the White House
3 trades disclosed in the last six months. The newest:
About Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of COLL's score, with the points and the reason
- All 14 checks on COLL and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on COLL
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.